Optimized Long‐ TE 1 H sLASER MR Spectroscopic Imaging at 3T for Separate Quantification of Glutamate and Glutamine in Glioma
Journal of Magnetic Resonance Imaging · 2025
DOI: 10.1002/jmri.29787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, 2025. Verfasst von Seyma Alcicek und 10 weiteren Autor:innen. Beteiligte Einrichtung: Goethe University Frankfurt, University Hospital, Institute of Neuroradiology, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Glutamine, Glutamic Acid, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Discovery & Development Project Grant of the LOEWE Frankfurt Cancer Institute, Mildred-Scheel Career Center of the German Cancer Aid.
Abstract (Originalsprache)
Background
Glutamate and glutamine are critical metabolites in gliomas, each serving distinct roles in tumor biology. Separate quantification of these metabolites using in vivo MR spectroscopy (MRS) at clinical field strengths (≤ 3T) is hindered by their molecular similarity, resulting in overlapping, hence indistinguishable, spectral peaks.
Purpose
To develop an MRS imaging (MRSI) protocol to map glutamate and glutamine separately at 3T within clinically feasible time, using J‐modulation to enhance spectral differentiation, demonstrate its reliability/reproducibility, and quantify the metabolites in glioma subregions. Study Type Prospective. Population Phantoms, 5 healthy subjects, and 30 patients with suspected glioma. IDH wild‐type glioblastoma cases were evaluated to establish a uniform group. Field Strength/Sequence 3T, Research protocol: 2D 1 H sLASER MRSI (40 and 120 ms TE) with water reference, 3D T1‐weighted and 2D T2‐weighted. Trial‐screening process: T1‐weighted, T1‐weighted contrast‐enhanced, T2‐weighted, FLAIR. Assessment Spectral simulations and phantom measurements were performed to design and validate the protocol. Spectral quality/fitting parameters for scan‐rescan measurements were obtained using LCModel. The proposed long‐TE data were compared with short‐TE data. BraTS Toolkit was employed for fully automated tumor segmentation. Statistical Tests Scan‐rescan comparison was performed using Bland–Altman analysis. LCModel coefficient of modeling covariance (CMC) between glutamate and glutamine was mapped to evaluate their model interactions for each spectral fitting. Metabolite levels in tumor subregions were compared using one‐way ANOVA and Kruskal‐Wallis. A p value < 0.05 was considered statistically significant.
Results
Spectral quality/fitting parameters and metabolite levels were highly consistent between scan‐rescan measurements. A negative association between glutamate and glutamine models at short TE (CMC = −0.16 ± 0.06) was eliminated at long TE (0.01 ± 0.05). Low glutamate in tumor subregions (non‐enhancing‐tumor‐core: 5.35 ± 4.45 mM, surrounding‐non‐enhancing‐FLAIR‐hyperintensity: 7.39 ± 2.62 mM, and enhancing‐tumor: 7.60 ± 4.16 mM) was found compared to contralateral (10.84 ± 2.94 mM), whereas glutamine was higher in surrounding‐non‐enhancing‐FLAIR‐hyperintensity (9.17 ± 6.84 mM) and enhancing‐tumor (7.20 ± 4.42 mM), but not in non‐enhancing‐tumor‐core (4.92 ± 3.38 mM, p = 0.18) compared to contralateral (2.94 ± 1.35 mM). Data Conclusion The proposed MRSI protocol (~12 min) enables separate mapping of glutamate and glutamine reliably along with other MRS‐detectable standard metabolites in glioma subregions at 3T. Evidence Level 1 Technical Efficacy Stage 3
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Goethe University Frankfurt, University Hospital, Institute of Neuroradiology, Frankfurt am Main, Germany.
- University Cancer Center Frankfurt (UCT), Frankfurt am Main, Germany.
- LOEWE Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.
- German Cancer Research Center (DKFZ) Heidelberg, Germany and German Cancer Consortium (DKTK), Frankfurt am Main, Germany.
- Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Neurooncology, Frankfurt am Main, Germany.
- Goethe University Frankfurt, University Hospital, Institute of Neurology (Edinger-Institute), Frankfurt am Main, Germany.
ORCID-Profile: Seyma Alcicek
Förderung
- Discovery & Development Project Grant of the LOEWE Frankfurt Cancer Institute
- Mildred-Scheel Career Center of the German Cancer Aid
Zitieren
APA
Alcicek, S., Ronellenfitsch, M. W., Steinbach, J. P., Manzhurtsev, A., Thomas, D. C., Weber, K. J., Prinz, V., Forster, M. T., Hattingen, E., Pilatus, U., & Wenger, K. J. (2025). Optimized Long‐ TE 1 H sLASER MR Spectroscopic Imaging at 3T for Separate Quantification of Glutamate and Glutamine in Glioma. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.29787
Vancouver
Alcicek S, Ronellenfitsch MW, Steinbach JP, Manzhurtsev A, Thomas DC, Weber KJ, et al. Optimized Long‐ TE 1 H sLASER MR Spectroscopic Imaging at 3T for Separate Quantification of Glutamate and Glutamine in Glioma. Journal of Magnetic Resonance Imaging. 2025. doi:10.1002/jmri.29787
BibTeX
@article{Alcicek2025,
author = {Alcicek, Seyma and Ronellenfitsch, Michael W and Steinbach, Joachim P and Manzhurtsev, Andrei and Thomas, Dennis C and Weber, Katharina J and Prinz, Vincent and Forster, Marie-Thérèse and Hattingen, Elke and Pilatus, Ulrich and Wenger, Katharina J},
title = {Optimized Long‐ TE 1 H sLASER MR Spectroscopic Imaging at 3T for Separate Quantification of Glutamate and Glutamine in Glioma},
journal = {Journal of Magnetic Resonance Imaging},
year = {2025},
doi = {10.1002/jmri.29787}
}
EUVIMED